Raloxifene: Difference between revisions
m Protected "Raloxifene": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 16: | Line 16: | ||
---- | ---- | ||
{{FDA}} | {{FDA}} | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 15:32, 20 August 2012
WikiDoc Resources for Raloxifene |
Articles |
---|
Most recent articles on Raloxifene |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Raloxifene at Clinical Trials.gov Clinical Trials on Raloxifene at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Raloxifene
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Raloxifene Discussion groups on Raloxifene Patient Handouts on Raloxifene Directions to Hospitals Treating Raloxifene Risk calculators and risk factors for Raloxifene
|
Healthcare Provider Resources |
Causes & Risk Factors for Raloxifene |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Synonyms: RAL, Raloxifene Hcl, Raloxifene Hydrochloride, Raloxifeno, Raloxifenum, LY-139481
Brand Names: Evista, Keoxifene
Dosing and Administration
Adult women
PO 60 mg every day.
Adapted from the FDA Package Insert. Template:WH